06-CV4-MI.ppt

07/23/2009

Coronary Artery Disease

Coronary Artery Disease,

Angina and MI

? Most CAD nothing more than Atherosclerosis

in the coronary arteries

? Chronic leads to angina pectoris

? Acute is MI

¨C 700,000 new MIs in U.S.

¨C 500,000 recurrent MIs in U.S.

Risk Factors

? Major nonmodifiable

¨C Age/gender

¨C Family hx

? Major modifiable

¨C

¨C

¨C

¨C

¨C

¨C

¨C

Dyslipidemia

Hypertension

Smoking

DM, insulin resistance

Obesity

Sedentary

Atherogenic diet

? Nonconventional

¨C HS CRP

¨C Homocysteine

¨C Lp(a)

Coronary Arteries

? Coronary Arteries surround and then

penetrate the heart muscle

¨C Right coronary artery (RCA) (back of heart)

¨C Left (Main) coronary artery

? Left circumflex (Side)

? Left anterior descending (Front)

1

07/23/2009

Myocardial Ischemia

? Blood flow must be impeded before heart

metabolism is affected

¨C Absolute

¨C Relative

? Causes

Supply/Demand Considerations

? Oxygen supply

¨C

¨C

¨C

¨C

Cardiac output

Hemoglobin levels

Respiratory function

Fitness of muscle

? Oxygen demand

¨C Atherosclerosis, Vasospasm

¨C Hypotension, Arrythmias, Anemia, V/Q

¨C Work of the heart

? Contractility

? HR

¨C Hypertrophy of the heart

Myocardial Ischemia

? Myocardium becomes ischemic within 10

seconds of coronary occlusion

? Working cells remain viable for up to 20

minutes

¨C Anaerobic mechanisms kick in

? Lactic acid

? Free radical damage, esp after reperfusion

Cardiac Ischemia Manifestation

? Stable angina

¨C Chronic obstruction

¨C Chest pain with exertion

¨C May radiate, may have diaphoresis, SOB, pallor

¨C Relief with rest or nitrates

? Prinzmetal angina

? Silent ischemia

? Unstable angina

¨C May become a myocardial infarction

Evaluation

?

?

?

?

?

?

H&P

Lipids, BP, risk factor assessment

ECG

Stress test

Angiography

Unstable angina

¨C Cardiac enzymes (rule in/out for MI)

Treatment for Stable Angina

? Drug

¨C Nitrates

¨C Beta blockers

¨C Calcium Channel Blockers

¨C Atherosclerotic disease tx (HTN, Lipids)

? Surgery

¨C Bypass

¨C PCI (PTCA, Stent)

¨C Experimental

2

07/23/2009

Acute Coronary Syndrome

Acute Coronary Syndrome

Atherosclerotic Plaque

? Unstable Angina ¨C reversible ischemia

¨C Rupture of an unstable plaque

¨C Clots spontaneously resolve over time

¨C Damage depends on size of clot and rate of

dissolution vs. rate of clot formation

¨C Myocardial infarction

Stable Plaque

Unstable Plaque

Stable Angina

Acute Coronary Syndrome

Transient

Ischemia/

Unstable

Angina

Sustained

Ischemia

Myocardial

Infarction

Necrosis

MI Pathophysiology

? Plaque rupture --> Clotting cascade active

? Thrombus occludes vessel

? Myocardium becomes hypoxic

¨C Shift to Anaerobic Respiration

¨C Waste products release/hypoxic injury

¨C Cardiac output impaired

? Norepinephrine/Epinephrine Release

? Renin release

Ischemic Morphology

? Increased O2 demand: epinephrine, RAAS

? Hypoactive wall/Necrosis

¨C Transmural

¨C Subendocardial

? Conductile problems

¨C PVCs

¨C Dysrhythmias

Myocardial Changes

? Myocardial stunning

¨C Temporary loss of contractility that persists for

hours to days

? Myocardial hibernation

¨C Chronically ischemic; myocytes are hibernating to

preserve function until perfusion can be restored

? Myocardial remodeling

¨C Loss of contractility mediated by Ang II,

catecholamines, and inflammatory cytokines

ECG changes

? Conductile cells of heart are most sensitive to

hypoxia

? Classic: T-wave inversion, ST-elevation, Q waves

? Non-Q wave MI: no Q waves, possibly normal

ST segment

? R/O CANNOT be made with ECG alone!!!

3

07/23/2009

MI Manifestations

? Prodromal

¨C Symptoms usually appear 24-72 hours before

¨C Malaise, Tiredness, Weakness fatigue

¨C Visual disturbance

? Acute Phase

¨C Symptoms: Chest Pain, Dyspnea, Nausea,

Diaphoresis, weakness, fatigue, anxiety

¨C Signs: Gray/ashen, gasping, clutching, loss of

consciousness, confused, ECG changes,

tachycardia, tachypnea

Eval & Tx

? ECG

? Cardiac Enzymes X 4

¨C If Ruled in

? Anticoagulation, antiplatelet

? Thrombolytic Therapy

? Cath lab, Emergency bypass

¨C If Ruled out

? Stress test

? Angiogram

Nitroglycerine

? Vasodilating actions

¨C Primarily acts on veins and large arteries

¨C Uptake by VSM cells and converts to active form:

NO

? Therapeutic uses: Stable Angina

¨C Decreases preload  decreases contraction 

oxygen demand

¨C Does not dilate coronary arteries

? MONA: Morphine, O2, Nitrates, ASA

Nitrates

? Kinetics

¨C Highly lipid soluble: can be given PO, IV, SL,

transdermal

¨C Rapid inactivation by organic nitrate reductases

¨C Half-life 5 ¨C 7 minutes

¨C PO: most drug is destroyed in liver before reaching

systemic circulation

? Adverse Effects

¨C Headache

¨C Orthostatic Hypotension

¨C Reflex tachycardia

Nitrates

? Interactions

¨C Other hypotensive drugs

¨C Beta blockers, verapamil, diltiazem

¨C Sildenafil (Viagra) ¨C life threatenening: 25 mmHg

drop

? Tolerance

¨C Most common in high dose, continuous therapy

¨C Prevent by using lower dose intermittent therapy:

8 hour drug free time

4

07/23/2009

Nitrates

? Preparations

¨C Sublingual: works in 1 ¨C 3 minutes; lasts an hour; expires within

6 months of opening

¨C Translingual spray

¨C Topical Ointment

¨C Transdermal patch

¨C PO Sustained release capsules or tablets: higher doses d/t first

pass effect (isosorbide mononitrate, dinitrate)

¨C IV infusion: glass bottle, special (vented) tubing

? Nursing implications

¨C Check BP before and after administering

¨C Assess for headache

¨C Discontinue slowly if patient has been on it for a while

Immediate Post MI Tx

? Most common cause of death within 72 hours

of MI is ________________

¨C Must be monitored

?

?

?

?

Reduce myocardial workload

Prevent Remodeling

Reduce chances of reocclusion

Reduce oxidative stress (reperfusion injury)

Post MI Evaluation

? Stress test

? Angiography

? Symptoms

Post MI Treatment

? Lifestyle

¨C Diet

¨C Exercise ¨C Cardiac Rehab

¨C Stress management

? Drugs

¨C Antiplatelet: ASA, clopidogrel, persantine

¨C Beta blocker

¨C Statin medication

¨C Treat risk factors (HTN, lipid, smoke, etc.)

¨C Sometimes coumadin

Clot Review

? Platelet aggregation

¨C Become sticky

¨C Activate GP IIb/IIIa

receptors

¨C Chemicals

? Prostaglandins

? Thromboxanes

? ADP

? Clot Stabilization

¨C Activation of

fibrinogen

¨C Binds to GP IIb/IIIa

¨C Chemicals

? Clotting cascade 

Thrombin 

Fibrinogen activation

5

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download